Caroline Dorsa bought $152k of BIIB
director at BIOGEN INC.. 1,235 shares at an average of $122.72, traded May 2, 2025, filed May 5, 2025.
Score components
- +15RoleDirector
- +11Trade size$152k at market
- 0Relative to holdingsHoldings up 4.6%
- +18Price context9% above the 52-week low; 39% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.3%, 3m +8.5%, 6m +24.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-013345, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 2, 2025 | POpen-market purchase Common Stock | +1,235 | $122.72 | $152k | 27,842 | May 5, 2025 |
Related signals
Other insiders at BIOGEN INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | BIOGEN INC. | Lloyd Minor director | $240k 1,186 shares | -31% | |
| 10Weak | BIIBbuy BIOGEN INC. | Nicole Murphy Head of Pharm Ops and Tech | $585 3 shares | +0% | |
| 3Weak | BIOGEN INC. | Priya Singhal Head of Development | $532k 2,660 shares | -25% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $134k 748 shares | -11% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $69k 517 shares | -8% | |
| 19Weak | BIOGEN INC. | Rachid Izzar Head of Global Product Strat. | $300k 2,223 shares | -26% | |
| 23Weak | BIOGEN INC. | Priya Singhal Head of Development | $481k 3,806 shares | -41% | |
| 30Weak | BIOGEN INC. | Stephen A Sherwin director | $1.3M 8,760 shares | -44% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $17k 110 shares | -2% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $88k 431 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.